Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new meta-analysis finds that prophylactic mechanical circulatory support devices — including LVADs, balloon pumps, and ECMO — don't reduce the risk of major cardiovascular events in patients undergoing complex, high-risk coronary stenting. The findings, published in the Journal of the American Heart Association, suggest these devices should be reserved for highly selected patients rather than used routinely.
A new network meta-analysis challenges the routine use of mechanical circulatory support (MCS) devices in high-risk coronary stenting procedures. Pooling data from eight randomized trials involving 1,856 patients, researchers found that prophylactic use of devices — including percutaneous left ventricular assist devices (LVADs), intra-aortic balloon pumps (IABP), and venoarterial ECMO — failed to reduce major adverse cardiovascular events (MACE) compared to standard care, both at 30 days and over a mean follow-up of nearly 11 months.
There was one nuance worth noting: percutaneous LVADs and IABPs were associated with fewer periprocedural complications compared to standard care. However, that benefit did not translate into improved long-term outcomes for death, stroke, heart attack, or repeat procedures.
By the Numbers:
Why it matters: MCS devices are costly, invasive, and carry their own risks. These findings push back against their routine prophylactic use in high-risk PCI, urging clinicians to reserve them for carefully selected patients — a shift that could meaningfully impact clinical practice and resource allocation.
